Main content area

Pharmacokinetic behaviour of enrofloxacin in greater rheas following a single-dose intramuscular administration

Lucas, J.J. de, Navarro, J.L., Rubio, S., Vignolo, P.E., Asis, V.C., Gonzalez, F., Rodriguez, C.
Veterinary journal 2008 v.175 no.1 pp. 136-138
rheas, Rhea, veterinary drugs, enrofloxacin, drug evaluation, pharmacokinetics, dosage, intramuscular injection, young animals, blood chemistry, metabolites, ciprofloxacin, half life, drug therapy, bacterial infections
The pharmacokinetic behaviour of enrofloxacin in greater rheas was investigated after intramuscular (IM) administration of 15 mg/kg. Plasma concentrations of enrofloxacin and its active metabolite, ciprofloxacin, were determined by high performance liquid chromatography. Enrofloxacin peak plasma concentration (Cmax = 3.30 ± 0.90 μg/mL) was reached at 24.17 ± 9.17 min. The terminal half-life (t1/2λ) and area under the curve (AUC) were 2.85 ± 0.54 h and 4.18 ± 0.69 μg h/mL, respectively. The AUC and Cmax for ciprofloxacin were 0.25 ± 0.06 μg/mL and 0.66 ± 0.16 μg h/mL, respectively. Taking into account the values obtained for the efficacy indices, an IM dose of 15 mg/kg of enrofloxacin would appear to be adequate for treating infections caused by highly susceptible bacteria (MIC90 < 0.03 μg/mL) in greater rheas.